Department of Gynecology and Obstetrics.
Division of Maternal Fetal Medicine and Clinical Pharmacology, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
AIDS. 2021 Jul 1;35(8):1319-1320. doi: 10.1097/QAD.0000000000002880.
This retrospective study of 100 pregnant women living with HIV [66 on tenofovir disoproxil fumarate (TDF) compared to 34 women on tenofovir alafenamide (TAF)] found no significant difference in renal function in pregnant women with HIV receiving TDF versus TAF. Our results demonstrate that, in regard to renal toxicity, both TDF and TAF appear to be safe for pregnant women living with HIV, but larger prospective cohort studies in pregnant women living with HIV are encouraged.
本回顾性研究纳入了 100 名 HIV 阳性孕妇[66 名接受富马酸替诺福韦二吡呋酯（TDF）治疗，34 名接受替诺福韦艾拉酚胺（TAF）治疗]，结果发现，接受 TDF 或 TAF 治疗的 HIV 阳性孕妇的肾功能无显著差异。我们的研究结果表明，在肾毒性方面，TDF 和 TAF 似乎对 HIV 阳性孕妇都是安全的，但仍鼓励开展针对 HIV 阳性孕妇的更大规模前瞻性队列研究。
